Tarrytown, NY, United States of America

David Esopi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Esopi: Innovator in Hydroxy Steroid Research

Introduction

David Esopi is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of biochemistry, particularly in the area of hydroxy steroid dehydrogenases. His work focuses on developing methods for screening modulators of the HSD17B family of proteins, which play a crucial role in various liver diseases.

Latest Patents

David Esopi holds a patent for "Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family." This patent includes innovative screening methods and kits designed to identify modulators of HSD17B family member proteins, such as HSD17B13. The methods involve assessing the capacity of molecules to modulate these proteins, which can be measured through various biochemical assays. The inhibitors identified through these methods have potential therapeutic applications for treating liver diseases and disorders.

Career Highlights

David Esopi is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in the field of hydroxy steroid dehydrogenases. His work is instrumental in developing new therapeutic strategies for conditions related to HSD17B family member proteins.

Collaborations

David collaborates with esteemed colleagues, including Panayiotis Stevis and Jesper Gromada. Their combined expertise enhances the research efforts at Regeneron Pharmaceuticals, fostering innovation in the field.

Conclusion

David Esopi's contributions to the field of biochemistry, particularly through his patent on HSD17B family member proteins, highlight his role as an innovator in medical research. His work has the potential to lead to significant advancements in the treatment of liver diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…